Sign Up for Alerts
Sign up to receive receive industry-specific emails from our legal team.
Sign Up for Alerts
We provide tailored, industry-specific legal updates to our clients and other friends of the firm.
Areas of Interest
January 29th, 2023
First NFT Trademark Trial Pits Hermès Against Metabirkin Artist
Blockchain Technology Co-Chair Jeremy S. Goldman is quoted in the article, “First NFT Trademark Trial Pits Hermès Against Metabirkin Artist” published by Bloomberg Law. The article discusses the French luxury brand Hermès International SA’s trademark trial against digital artist Mason Rothschild. Hermès is arguing that Rothschild violated trademark law by creating and selling “MetaBirkin” NFTs that depict digital images of the famous Birkin handbag. The trial is expected to test the boundaries of artistic expression and how nonfungible tokens are viewed in the eyes of decades-old intellectual property law. Jeremy is quoted saying, “Deciding whether an NFT project is protected art or if it is a digital knockoff subject to trademark law is no easy job. You could have a one-of-one, oil-on-canvas painting that gets sold in a gallery and no one would treat that as merchandise or as a consumer product. But if you take that same painting, and you put it on posters, and you sell 100 of them, then it starts to look more like a commercial product.”
Read the full article and Jeremy’s quotes here.
Other Quoted
‘I have been hunted down by HR reps, lawyers, and comms people:’ Developers discuss the pain and prevalence of side work clauses
Wendy Stryker was quoted in a Game Developer article discussing "side work clauses," also known as "moonlighting clauses," in video game industry employment contracts. Read more.
July 30 2026
Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads
Jeffrey A. Greenbaum was quoted in the Regulatory Affairs Professionals Society (RAPS) article, "Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads." The article discusses the FDA's proposal to eliminate the "adequate provision" requirement in direct-to-consumer (DTC) prescription drug advertising, a change that experts say could effectively result in a de facto ban on prescription drug advertisements. Read more.
July 21 2026
What Cannes Lions Can Teach Us About Advertising’s Most Important Customer
Cannes Lions brought important conversations to the stage about advertising’s most important stakeholder: the public. Read more.
July 2 2026
